Format

Send to

Choose Destination
Therap Adv Gastroenterol. 2018 Mar 21;11:1756284818759483. doi: 10.1177/1756284818759483. eCollection 2018.

Host-targeting therapies for hepatitis C virus infection: current developments and future applications.

Author information

1
Institut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France Université de Strasbourg, Strasbourg, France.
2
Institut National de la Santé et de la Recherche Médicale (Inserm), U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France Université de Strasbourg, Strasbourg, France Inserm U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL), Université de Lyon (UCBL), Lyon, France.
3
Inserm U1110, Institut de Recherches sur les Maladies Virales et Hépatiques, Université de Strasbourg, 3 Rue Koeberlé, F-67000 Strasbourg, France.

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with considerable improvement of sustained virologic response in patients. Today, DAAs have become the standard of care for HCV therapy. However, several limitations remain, which include access to therapy, treatment failure in a subset of patients and persistent risk of HCC development following cure in patients with advanced fibrosis. By targeting conserved host proteins involved in the HCV life cycle, host-targeting agents (HTAs) offer opportunities for pan-genotypic antiviral approaches with a high barrier to drug resistance. Moreover, when applied in combination with DAAs, HTAs could improve the management of difficult-to-treat patients by acting through a complementary mechanism of action. In this review, we summarize the different HTAs evaluated in preclinical and clinical development and discuss their potential role for anti-HCV therapies.

KEYWORDS:

clinical trial; direct-acting antivirals; hepatitis C virus; host-targeting agents; treatment

Conflict of interest statement

Conflict of interest statement: C.S., M.B.Z. and T.F.B are inventors of patents or patent applications on anti-receptor antibodies for prevention and treatment of HCV infection.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center